Differences on the Mechanism of Action between the Radiolabeled Somatostatin Receptor Antagonist 177Lu-OPS201 and the Agonist 177Lu-DOTA-TATE: an in vitro Investigation

被引：0
|
作者：
Mansi, R. [1 ]
Santoianni-Klauer, D. [1 ]
Del Pozzo, L. [1 ]
Plas, P. [2 ]
Fani, M. [1 ]
机构：
[1] Univ Basel, Univ Hosp Basel, Basel, Switzerland
[2] Inst Henri Beaufour, Ipsen, Les Ulis, France
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-024
引用
收藏
页码：S14 / S15
页数：2
相关论文
共 50 条
  • [41] A Phase II Trial to Evaluate the Safety and Dosimetry of [177Lu] Lu-DOTA-TATE in Adolescent Patients With Somatostatin Receptor (SSTR)-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs)
    O'Dorisio, M. Sue
    Gaze, Mark
    Sabado, Constantino
    Brouri, Fazia
    Folitar, Ilya
    PANCREAS, 2022, 51 (03) : E59 - E59
  • [42] A phase II trial to evaluate the safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), pheochromocytomas and paragangliomas (PPGLs)
    Gaze, M. N.
    O'Dorisio, M. S.
    Sabado, C.
    Brouri, F.
    Folitar, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S920 - S920
  • [43] Incidence of raised HbA1c and correlation with Somatostatin analogue therapy (SSA) in patients with Neuroendocrine Tumours (NET) receiving peptide receptor [177Lu]Lu-DOTA-TATE radionuclide therapy (PRRT)
    Eftychiou, N.
    Ilyas, H.
    Ahmed, H.
    Hassan, F.
    Eccles, A.
    Lewington, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S469 - S470
  • [44] Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literature Review
    Hertelendi, Marianna
    Belguenani, Oulaya
    Cherfi, Azzeddine
    Folitar, Ilya
    Kollar, Gabor
    Polack, Berna Degirmenci
    BIOMEDICINES, 2023, 11 (04)
  • [45] Safety, Pharmacokinetics and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors: A Phase 1 First-in-human Study
    Zhang, Jingjing
    Niu, Gang
    Wang, Hao
    Jacobson, Orit
    Cheng, Yuejuan
    Zang, Jie
    Li, Fang
    Bai, Chunmei
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [46] Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK
    Murphy, Ravindhi
    Chander, Gurvin
    Martinez, Maria
    Ward, Caroline
    Khan, Sairah R.
    Naik, Mitesh
    Barwick, Tara
    Aboagye, Eric
    Sharma, Rohini
    BMJ OPEN, 2023, 13 (10):
  • [47] LANTana: A phase Ib study nvestigating epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]-DOTA-TATE in patients with metastatic neuroendocrine tumours
    Sharma, R.
    Khan, S. R.
    Naik, M.
    Barwick, T. D.
    Aboagye, E. O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S761 - S761
  • [48] First-in-human study of a novel SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with advanced metastatic NENs and low SSTR agonist binging
    Zhang, Jingjing
    Singh, Aviral
    Schuchardt, Christiane
    Maecke, Helmut
    Mueller, Dirk
    Kulkarni, Harshad
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [49] Impact of two cycles of peptide receptor radionuclide therapy (PRRT) on renal function as determined by repeated Tc-99m DTPA/GFR measurements: comparison between Y-90 DOTA-TATE and Lu-177 DOTA-TATE
    Prasad, V.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S325 - S325
  • [50] Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3 A Somatostatin Receptor Antagonist
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Singh, Aviral
    Baum, Richard P.
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (03) : E165 - E168
12345